Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical Trials

Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical Trials

COVID-19 pandemic demands a swift response to find therapeutic tools that effectively reduce morbidity and mortality. Despite initial fears, evidence from retrospective observational studies supports the inhibition of the renin-angiotensin system as an emerging pathway to delay or moderate angiotens...

Full description

Bibliographic Details
Main Authors: Rodolfo Pedro Rothlin, Mariano Duarte, Facundo Germán Pelorosso, Liliana Nicolosi, M. Victoria Salgado, Héctor Miguel Vetulli, Eduardo Spitzer
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Pharmacology
Subjects:
angiotensin receptor blocker
clinical trial
telmisartan
valsartan
losartan
COVID-19
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.603736/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.603736/full

Similar Items